Developer docs
API playgroundTry for free, no card

Search company profiles

Braveheart Bio

Full company profile

uuid003b95a

Namestring
Braveheart Bio
Legal namestring
Braveheart Bio, Inc.
Websiteurl
braveheart.bio
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Braveheart Bio, Inc. is a clinical-stage biotechnology company headquartered in San Francisco that is developing BHB-1893 (also known as HRS-1893), a selective, reversible, small-molecule cardiac myosin inhibitor intended to treat hypertrophic cardiomyopathy (HCM), including both obstructive (oHCM) and non-obstructive (nHCM) forms. The asset was discovered and initially developed by Jiangsu Hengrui Pharmaceuticals and licensed worldwide (excluding Mainland China, Hong Kong SAR, Macao SAR, and Taiwan Region) to Braveheart in September 2025 for a $65 million upfront payment plus development and commercial milestones and royalties, with total potential deal value of up to approximately $1.013 billion. BHB-1893 is designed to modulate cardiac myosin activity, reducing hypercontractility while preserving left ventricular ejection fraction (LVEF), and has demonstrated a shallow EF exposure-response curve, simplified dosing with minimal titration, and positive Phase 2 results in both oHCM (42 patients, March 2026) and nHCM (84 patients, May 2026), with global pivotal Phase 3 development planned for 2026.

The company is pre-commercial and pre-revenue, with no approved products on the market. Braveheart launched publicly on November 5, 2025 alongside a $185 million Series A financing led by Andreessen Horowitz (a16z Bio + Health), Forbion, and OrbiMed, with participation from Enavate Sciences (a platform of Patient Square Capital) and Frazier Life Sciences. Its business model is therefore a venture-backed drug development model with future revenue expected to come from commercialization (or out-licensing) of BHB-1893 in the licensed ex-China territories through specialty cardiology channels, contingent on regulatory approval. Target customers are cardiologists and specialty HCM centers serving an HCM population of approximately 1 in 500 individuals in the United States (~700,000), of whom fewer than 20% of eligible oHCM patients currently receive targeted therapy. Leadership includes CEO Travis Murdoch (ex-HI-Bio/Biogen), CDO Michele Anderson (ex-Gilead/Biogen), CMO Emil deGoma (ex-Tourmaline Bio/Akebia), CSO Marc Evanchik (ex-MyoKardia/Edgewise, key contributor to Camzyos), and CFO Paul Rickey (Alpine Immune Sciences, acquired by Vertex), with Chris Viehbacher (former Biogen CEO) as Board Chair.

Short descriptiontext

Braveheart Bio is a clinical-stage biotechnology company developing BHB-1893, a selective cardiac myosin inhibitor in-licensed from Hengrui Pharma for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, backed by a $185 million Series A from top-tier biotech investors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiac myosin inhibitor, hypertrophic cardiomyopathy therapy, precision cardiovascular drug, rare disease biopharmaceutical, clinical-stage biotechnology
Industry1 code
PRIMARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Cardiovascular Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Licensing & milestone payments (in-licensed asset)
TypeLicensing Royalties
Description

Braveheart Bio is pre-commercial / pre-revenue. The company has not yet generated product revenue; its development is funded by venture capital plus in-licensed program economics. Per the September 2025 exclusive worldwide license (ex-Mainland China, Hong Kong SAR, Macao SAR, Taiwan Region) with Jiangsu Hengrui Pharma for HRS-1893, Braveheart paid a $65 million upfront and is obligated to pay development/commercial milestones plus royalties on sales. Hengrui is eligible for up to ~$1.013 billion in total deal value plus royalties.

pharmiweb.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Others
Pricing details1 tier
1Not publicly disclosed (pre-commercial clinical-stage biotech)
ModelOther
Notes

No product pricing available. Job-posting salary ranges disclosed for hiring purposes only.

braveheart.bio
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1BHB-1893
Description

Lead investigational product candidate, a selective, reversible small-molecule cardiac myosin inhibitor (also known as HRS-1893), being developed for hypertrophic cardiomyopathy (obstructive and non-obstructive).

braveheart.bio
Core offering1 text field

Braveheart Bio is a clinical-stage biotechnology company developing BHB-1893 (also known as HRS-1893), a selective, reversible, small-molecule cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy (HCM) in both its obstructive (oHCM) and non-obstructive (nHCM) forms. The asset was in-licensed from Jiangsu Hengrui Pharma under an exclusive worldwide license (excluding Mainland China, Hong Kong SAR, Macao SAR, and Taiwan Region) and is being advanced through global late-stage clinical development, with planned global pivotal Phase 3 trials in 2026.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Phase 2 oHCM: Valsalva LVOT-G complete response (<30 mmHg) of up to 86%; LVEF decrease only 1.8%-2.7%; KCCQ-CSS +10.5 points, pVO2 +1.0 mL/kg/min, NT-proBNP -88% in Group 2; 89% of patients well-served at 40 or 60 mg twice daily with minimal to no titration.
+1 more record
Product overview1 text field

Braveheart Bio's product offering is centered on a single investigational drug candidate — BHB-1893 (also referred to as HRS-1893, the designation used by originator Jiangsu Hengrui Pharma). There is no broader platform-plus-modules architecture; the company's portfolio revolves around advancing this one selective, small-molecule cardiac myosin inhibitor through global late-stage clinical development for hypertrophic cardiomyopathy (HCM). BHB-1893 and HRS-1893 refer to the same molecule (Braveheart Bio's development name and Hengrui's originator designation), being progressed in parallel Phase 2/3 programs for both the obstructive (oHCM) and non-obstructive (nHCM) forms of HCM under an exclusive worldwide licensing arrangement with Hengrui Pharma.

Product and service1 record
1BHB-1893 (also designated HRS-1893)
CategoryInvestigational small-molecule pharmaceutical (cardiac myosin inhibitor)
Description

BHB-1893 is a selective, reversible, small-molecule cardiac myosin inhibitor being developed as an investigational next-generation oral therapy for hypertrophic cardiomyopathy. It is engineered for rapid onset of action, minimal impact on left ventricular ejection fraction (LVEF), favorable safety, and simplified dosing with minimal titration. The candidate is being advanced through global Phase 2/3 clinical development for both obstructive (oHCM) and non-obstructive (nHCM) forms of HCM. Positive Phase 2 data have been reported in both oHCM (42 patients, NCT06516068) and nHCM (84 patients, NCT06816251). The molecule is also known as HRS-1893, the designation used by originator Jiangsu Hengrui Pharma.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Jiangsu Hengrui Pharma (Hengrui Pharma)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

Exclusive worldwide licensing agreement (ex-Mainland China, Hong Kong SAR, Macao SAR, and Taiwan Region) for the development, manufacture and commercialization of HRS-1893 (BHB-1893). $65 million upfront payment, with potential milestones and royalties, and total potential deal value of up to ~$1.013 billion. Hengrui continues to run the ongoing Phase 3 study in oHCM in China (NCT07021976). Braveheart and Hengrui jointly announce Phase 2 results in oHCM (March 30, 2026) and nHCM (May 11, 2026) and continue to co-develop the asset.

pharmiweb.com
Strategic tierCoreTypeGTM or Marketing Partner
Description

External communications/IR agency serving as Braveheart Bio's media contact (Braveheart-bio@fgsglobal.com) on official press releases including Phase 2 nHCM and oHCM announcements.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers7 records
TypeEmerging player
Description

Tenaya is developing TN-201, an adeno-associated virus gene therapy targeting MYBPC3 mutations, the most common genetic cause of HCM. It represents an emerging modality (gene therapy) competing in the same HCM patient population with a different mechanism of action.

TypeDirect peer
Description

Cytokinetics is developing aficamten, a next-generation cardiac myosin inhibitor for obstructive HCM, in late-stage clinical trials (SEQUOIA-HCM Phase 3). It is the closest direct competitor to Braveheart in the cardiac myosin inhibitor class for HCM and competes head-to-head for specialty cardiology market share upon approval.

TypeEmerging player
Description

Cardurion is a private cardiovascular-focused biotechnology company developing therapies for heart failure and related cardiac diseases, with a capital structure and clinical-development profile broadly comparable to Braveheart. It competes for capital, talent, and specialty cardiology commercial channels in adjacent indications.

TypeEmerging player
Description

Lexeo is developing cardiac-targeted genetic medicines including LX2000 for Friedreich's ataxia cardiomyopathy and programs in additional genetic cardiomyopathies. It overlaps with Braveheart's HCM focus area via disease-modifying approaches to inherited cardiac muscle disorders.

TypeBroad incumbent
Description

Alnylam markets Onpattro and Amvuttra for transthyretin amyloid cardiomyopathy and has a broader RNAi-based cardiovascular pipeline. It serves as a broader RNA/genetic medicines incumbent operating in cardiology specialty channels with overlapping patient populations (cardiac muscle disease).

6Bristol Myers Squibb
TypeBroad incumbent
Description

BMS owns Camzyos (mavacamten), the first-in-class cardiac myosin inhibitor approved for oHCM, acquired via the $13.1B MyoKardia deal. Camzyos is the established standard of care Braveheart must differentiate against and provides a direct comparator for efficacy, safety, dosing convenience, and commercial launch benchmarks.

TypeDirect peer
Description

Edgewise Therapeutics is developing EDG-7500, a novel cardiac sarcomere modulator for HCM and hypertrophic heart disease, with leadership and scientific staff overlapping the cardiac myosin inhibitor community. It is a smaller, earlier-stage direct competitor pursuing the same disease-modification thesis in HCM.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks3 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Braveheart Bio

Cardiovascular Therapeuticsbraveheart.bio

Braveheart Bio is a clinical-stage biotechnology company developing BHB-1893, a selective cardiac myosin inhibitor in-licensed from Hengrui Pharma for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, backed by a $185 million Series A from top-tier biotech investors.

What Braveheart Bio does

Braveheart Bio, Inc. is a clinical-stage biotechnology company headquartered in San Francisco that is developing BHB-1893 (also known as HRS-1893), a selective, reversible, small-molecule cardiac myosin inhibitor intended to treat hypertrophic cardiomyopathy (HCM), including both obstructive (oHCM) and non-obstructive (nHCM) forms. The asset was discovered and initially developed by Jiangsu Hengrui Pharmaceuticals and licensed worldwide (excluding Mainland China, Hong Kong SAR, Macao SAR, and Taiwan Region) to Braveheart in September 2025 for a $65 million upfront payment plus development and commercial milestones and royalties, with total potential deal value of up to approximately $1.013 billion. BHB-1893 is designed to modulate cardiac myosin activity, reducing hypercontractility while preserving left ventricular ejection fraction (LVEF), and has demonstrated a shallow EF exposure-response curve, simplified dosing with minimal titration, and positive Phase 2 results in both oHCM (42 patients, March 2026) and nHCM (84 patients, May 2026), with global pivotal Phase 3 development planned for 2026.

The company is pre-commercial and pre-revenue, with no approved products on the market. Braveheart launched publicly on November 5, 2025 alongside a $185 million Series A financing led by Andreessen Horowitz (a16z Bio + Health), Forbion, and OrbiMed, with participation from Enavate Sciences (a platform of Patient Square Capital) and Frazier Life Sciences. Its business model is therefore a venture-backed drug development model with future revenue expected to come from commercialization (or out-licensing) of BHB-1893 in the licensed ex-China territories through specialty cardiology channels, contingent on regulatory approval. Target customers are cardiologists and specialty HCM centers serving an HCM population of approximately 1 in 500 individuals in the United States (~700,000), of whom fewer than 20% of eligible oHCM patients currently receive targeted therapy. Leadership includes CEO Travis Murdoch (ex-HI-Bio/Biogen), CDO Michele Anderson (ex-Gilead/Biogen), CMO Emil deGoma (ex-Tourmaline Bio/Akebia), CSO Marc Evanchik (ex-MyoKardia/Edgewise, key contributor to Camzyos), and CFO Paul Rickey (Alpine Immune Sciences, acquired by Vertex), with Chris Viehbacher (former Biogen CEO) as Board Chair.

Braveheart Bio firmographics

Firmographics
Name
Braveheart Bio
Legal name
Braveheart Bio, Inc.
Website
https://braveheart.bio
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
51–100 employees
Short description
Braveheart Bio is a clinical-stage biotechnology company developing BHB-1893, a selective cardiac myosin inhibitor in-licensed from Hengrui Pharma for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, backed by a $185 million Series A from top-tier biotech investors.
Ownership category
akta.pro rank

Braveheart Bio industry classification

Industry
Product category
Cardiovascular Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Cardiac myosin inhibitor
  • Hypertrophic cardiomyopathy therapy
  • Precision cardiovascular drug
  • Rare disease biopharmaceutical
  • Clinical-stage biotechnology

Where Braveheart Bio is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Braveheart Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

  1. Licensing & milestone payments (in-licensed asset): Braveheart Bio is pre-commercial / pre-revenue. The company has not yet generated product revenue; its development is funded by venture capital plus in-licensed program economics. Per the September 2025 exclusive worldwide license (ex-Mainland China, Hong Kong SAR, Macao SAR, Taiwan Region) with Jiangsu Hengrui Pharma for HRS-1893, Braveheart paid a $65 million upfront and is obligated to pay development/commercial milestones plus royalties on sales. Hengrui is eligible for up to ~$1.013 billion in total deal value plus royalties.

Pricing tiers

ModelBillingPrice
Other—Not publicly disclosed (pre-commercial clinical-stage biotech)

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Braveheart Bio product offering

Product offering

Core offering

Braveheart Bio is a clinical-stage biotechnology company developing BHB-1893 (also known as HRS-1893), a selective, reversible, small-molecule cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy (HCM) in both its obstructive (oHCM) and non-obstructive (nHCM) forms. The asset was in-licensed from Jiangsu Hengrui Pharma under an exclusive worldwide license (excluding Mainland China, Hong Kong SAR, Macao SAR, and Taiwan Region) and is being advanced through global late-stage clinical development, with planned global pivotal Phase 3 trials in 2026.

Product overview

Braveheart Bio's product offering is centered on a single investigational drug candidate — BHB-1893 (also referred to as HRS-1893, the designation used by originator Jiangsu Hengrui Pharma). There is no broader platform-plus-modules architecture; the company's portfolio revolves around advancing this one selective, small-molecule cardiac myosin inhibitor through global late-stage clinical development for hypertrophic cardiomyopathy (HCM). BHB-1893 and HRS-1893 refer to the same molecule (Braveheart Bio's development name and Hengrui's originator designation), being progressed in parallel Phase 2/3 programs for both the obstructive (oHCM) and non-obstructive (nHCM) forms of HCM under an exclusive worldwide licensing arrangement with Hengrui Pharma.

Differentiator

Problem solved

Functional benefit

Brands

  • BHB-1893: Lead investigational product candidate, a selective, reversible small-molecule cardiac myosin inhibitor (also known as HRS-1893), being developed for hypertrophic cardiomyopathy (obstructive and non-obstructive).

Products and services

  • BHB-1893 (also designated HRS-1893) BHB-1893 is a selective, reversible, small-molecule cardiac myosin inhibitor being developed as an investigational next-generation oral therapy for hypertrophic cardiomyopathy. It is engineered for rapid onset of action, minimal impact on left ventricular ejection fraction (LVEF), favorable safety, and simplified dosing with minimal titration. The candidate is being advanced through global Phase 2/3 clinical development for both obstructive (oHCM) and non-obstructive (nHCM) forms of HCM. Positive Phase 2 data have been reported in both oHCM (42 patients, NCT06516068) and nHCM (84 patients, NCT06816251). The molecule is also known as HRS-1893, the designation used by originator Jiangsu Hengrui Pharma.

Quantifiable outcome

  • Phase 2 oHCM: Valsalva LVOT-G complete response (<30 mmHg) of up to 86%; LVEF decrease only 1.8%-2.7%; KCCQ-CSS +10.5 points, pVO2 +1.0 mL/kg/min, NT-proBNP -88% in Group 2; 89% of patients well-served at 40 or 60 mg twice daily with minimal to no titration.
  • +1 more outcomes

Companies that use Braveheart Bio

Customer profile

Named customers1 record

Ideal customer profiles1 record

Braveheart Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Braveheart Bio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and core.

  • Jiangsu Hengrui Pharma (Hengrui Pharma)flagshipStrategic or Co-development Partner · 1 September 2025Exclusive worldwide licensing agreement (ex-Mainland China, Hong Kong SAR, Macao SAR, and Taiwan Region) for the development, manufacture and commercialization of HRS-1893 (BHB-1893). $65 million upfront payment, with potential milestones and royalties, and total potential deal value of up to ~$1.013 billion. Hengrui continues to run the ongoing Phase 3 study in oHCM in China (NCT07021976). Braveheart and Hengrui jointly announce Phase 2 results in oHCM (March 30, 2026) and nHCM (May 11, 2026) and continue to co-develop the asset.
  • FGS GlobalcoreGTM or Marketing PartnerExternal communications/IR agency serving as Braveheart Bio's media contact (Braveheart-bio@fgsglobal.com) on official press releases including Phase 2 nHCM and oHCM announcements.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Braveheart Bio competitors and assessment

Company assessment

Emerging players

  • Tenaya Therapeutics: Tenaya is developing TN-201, an adeno-associated virus gene therapy targeting MYBPC3 mutations, the most common genetic cause of HCM. It represents an emerging modality (gene therapy) competing in the same HCM patient population with a different mechanism of action.
  • Cardurion Pharmaceuticals: Cardurion is a private cardiovascular-focused biotechnology company developing therapies for heart failure and related cardiac diseases, with a capital structure and clinical-development profile broadly comparable to Braveheart. It competes for capital, talent, and specialty cardiology commercial channels in adjacent indications.
  • Lexeo Therapeutics: Lexeo is developing cardiac-targeted genetic medicines including LX2000 for Friedreich's ataxia cardiomyopathy and programs in additional genetic cardiomyopathies. It overlaps with Braveheart's HCM focus area via disease-modifying approaches to inherited cardiac muscle disorders.

Direct peers

  • Cytokinetics: Cytokinetics is developing aficamten, a next-generation cardiac myosin inhibitor for obstructive HCM, in late-stage clinical trials (SEQUOIA-HCM Phase 3). It is the closest direct competitor to Braveheart in the cardiac myosin inhibitor class for HCM and competes head-to-head for specialty cardiology market share upon approval.
  • Edgewise Therapeutics: Edgewise Therapeutics is developing EDG-7500, a novel cardiac sarcomere modulator for HCM and hypertrophic heart disease, with leadership and scientific staff overlapping the cardiac myosin inhibitor community. It is a smaller, earlier-stage direct competitor pursuing the same disease-modification thesis in HCM.

Broad incumbents

  • Alnylam Pharmaceuticals: Alnylam markets Onpattro and Amvuttra for transthyretin amyloid cardiomyopathy and has a broader RNAi-based cardiovascular pipeline. It serves as a broader RNA/genetic medicines incumbent operating in cardiology specialty channels with overlapping patient populations (cardiac muscle disease).
  • Bristol Myers Squibb: BMS owns Camzyos (mavacamten), the first-in-class cardiac myosin inhibitor approved for oHCM, acquired via the $13.1B MyoKardia deal. Camzyos is the established standard of care Braveheart must differentiate against and provides a direct comparator for efficacy, safety, dosing convenience, and commercial launch benchmarks.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks3 records

Key highlights7 records

Customer concentration

Braveheart Bio social profiles

Digital presence

Braveheart Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Braveheart Bio leadership team

Management profile

Number of profiles

Profiles15 records

Braveheart Bio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Braveheart Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Braveheart Bio

What does Braveheart Bio do?

Braveheart Bio is a clinical-stage biotechnology company developing BHB-1893 (also known as HRS-1893), a selective, reversible, small-molecule cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy (HCM) in both its obstructive (oHCM) and non-obstructive (nHCM) forms. The asset was in-licensed from Jiangsu Hengrui Pharma under an exclusive worldwide license (excluding Mainland China, Hong Kong SAR, Macao SAR, and Taiwan Region) and is being advanced through global late-stage clinical development, with planned global pivotal Phase 3 trials in 2026.

Is Braveheart Bio a public or private company?

Braveheart Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Braveheart Bio founded?

Braveheart Bio was founded in 2025. It employs 51 to 100 people.

Where is Braveheart Bio based?

Braveheart Bio is headquartered in San Francisco, United States, in the North America region.

How does Braveheart Bio make money?

One revenue line is on record: licensing & milestone payments (in-licensed asset).

Who are Braveheart Bio's main competitors?

Emerging players on record are Tenaya Therapeutics, Cardurion Pharmaceuticals and Lexeo Therapeutics. Direct peers are Cytokinetics and Edgewise Therapeutics. Broad incumbents are Alnylam Pharmaceuticals and Bristol Myers Squibb.

Does Braveheart Bio have an API?

No public API is recorded for Braveheart Bio.

What industry is Braveheart Bio in?

Braveheart Bio's product category is Cardiovascular Therapeutics. Its primary akta.pro industry code is HLAIAIAH, Rare Cardiovascular & Vascular Disorder Therapies. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comStifel reiterates Buy rating on Braveheart Bio stock, $45 targetStifel reiterated a Buy rating on Braveheart Bio with a $45 price target after the company's Q3 2026 update. The target implies upside from the current $19.62 price, with consensus Strong Buy and targets of $40–$48. Key trials, including Hengrui's phase 3 and Braveheart's interim results, are expected in 2027.Business & FinancialBraveheart Bio To Participate In The Jefferies Global Healthcare Conference In LondonBraveheart Bio will participate in the Jefferies Global Healthcare Conference in London, with a live webcast available on its website. The company's lead product candidate BHB-1893 is a cardiac myosin inhibitor for hypertrophic cardiomyopathy, aiming to address limitations of existing treatments.The future of tradingHengrui's HRS/BHB-1893 Improves Exercise Capacity in 52-Week Phase 2 Extension StudyHengrui Pharma and Braveheart Bio presented Phase 2 extension results for HRS/BHB-1893 at the American Heart Association Scientific Sessions on November 6, 2026. The 52-week extension enrolled 42 adults with symptomatic obstructive hypertrophic cardiomyopathy, and the drug improved exercise capacity and symptoms with sustained reductions in obstruction. No severe or serious adverse events occurred, and most patients remained on the starting dose.YahooBraveheart Bio Shares One-Year Heart Drug Data, Plans New Fixed-Dose TrialBraveheart Bio presented one-year data from an open-label extension of its heart drug BHB-1893, showing improved exercise capacity and symptoms in 42 patients with obstructive HCM. The company plans to start a fixed-dose Phase IIb trial in 2027 and expects Phase III results in 2027, with cash runway into 2029.TradingViewBraveheart Bio Reports 52-Week HRS/BHB-1893 Data in Obstructive HCMBraveheart Bio reported 52-week Phase 2 extension data for HRS/BHB-1893 in obstructive hypertrophic cardiomyopathy, showing peak oxygen uptake rose 2.7 mL/kg/min and KCCQ-CSS increased 17.3 points. 79% of patients had a Valsalva LVOT gradient below 30 mmHg, and no severe or serious adverse events occurred. The company plans to discuss a fixed-dose Phase 2b study, TRUEHEART-HCM, at an investor event.TradingViewHengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026Hengrui Pharma and Braveheart Bio presented 52-week open-label extension data for HRS/BHB-1893 in obstructive hypertrophic cardiomyopathy at AHA 2026. At Week 52, peak oxygen uptake increased by 2.7 mL/kg/min and KCCQ-CSS by 17.3 points, with 79% achieving Valsalva LVOT gradient <30 mmHg. The data support a simplified dosing regimen and potential reverse-remodeling.TradingViewBraveheart Bio (BRVE) Reports 52-Week HCM Drug Study ResultsBraveheart Bio reported 52-week results from a 42-patient open-label extension of its HCM drug HRS/BHB-1893, showing improved exercise capacity and symptom scores. At Week 52, 79% of patients had a Valsalva LVOT gradient below 30 mmHg, and no on-treatment severe or serious adverse events occurred. The company plans a fixed-dose Phase 2b oHCM study.Stock TitanBraveheart Bio 52-week trial: 57% stayed on starting doseHengrui Pharma and Braveheart Bio presented 52-week open-label extension data for HRS/BHB-1893 in obstructive hypertrophic cardiomyopathy at AHA 2026. At Week 52, 57% of patients remained on the 40 mg BID starting dose, and 79% achieved a Valsalva LVOT gradient below 30 mmHg. The data support a simplified dosing regimen and potential reverse-remodeling.GlobeNewswireHengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026Hengrui Pharma and Braveheart Bio presented 52-week open-label extension data for HRS/BHB-1893 in obstructive hypertrophic cardiomyopathy at AHA 2026. At Week 52, peak oxygen uptake increased by 2.7 mL/kg/min, KCCQ-CSS by 17.3 points, and 79% of patients achieved a Valsalva LVOT gradient below 30 mmHg. The data support a simplified dosing regimen and potential reverse-remodeling.FinancialContent Business PageHengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific SeHengrui Pharma and Braveheart Bio presented 52-week open-label extension data for HRS/BHB-1893 in obstructive hypertrophic cardiomyopathy at the AHA Scientific Sessions. At Week 52, peak oxygen uptake increased by 2.7 mL/kg/min and KCCQ-CSS by 17.3 points, with 79% of patients achieving a Valsalva LVOT gradient below 30 mmHg. The data support a simplified dosing regimen and potential reverse-remodeling.